Sun Pharma Q3 Preview: Firm likely to post healthy set of numbers; gRevlimid sales expected to be around Rs 4.5 crore

Sun Pharma Q3 Preview: Sun Pharmaceutical Industries, the multinational pharmaceutical company headquartered in Mumbai, is scheduled to release its December quarter (Q3 FY24) results on Wednesday, January 31. The pharma major, as per analysts, is slated to report a healthy set of numbers for the quarter under review.

According to Zee Business Research desk, consolidated revenue at the company is expected to grow 9.5 per cent year-on-year (YoY) to Rs 12,303 crore against Rs 11,241 crore logged in the year-ago period. EBITDA, or earnings before interest, taxes, depreciation, and amortisation, is pegged at Rs 3,259 crore, up 8.5 per cent YoY. In the corresponding quarter of the previous fiscal, EBITDA stood at Rs 3,004 crore.

Margins are estimated to remain flat at 26.5 per cent against 26.7 per cent registered in Q3 FY23. Net profit, or profit after tax (PAT), is seen rising 10 per cent YoY to Rs 2,400 crore against Rs 2,181 crore in the December quarter of FY23.

Further, the desk estimates the company's American business revenue to grow 9 per cent YoY, while the US specialty is expected to post double-digit growth. Meanwhile, domestic business is expected to see 8 per cent growth.

gRevlimid sales are expected to be around Rs 4.5 crore. Key things to watch out for include launches in the coming 12–15 months and R&D spending.

Sun Pharma Q2 results

Sun Pharmaceutical Industries' consolidated net profit increased by 5 per cent to Rs 2,375 crore for the second quarter ended September 30, driven by robust sales across domestic and US markets. The drug major reported a net profit of Rs 2,262 crore in the July–September period of the last fiscal.

Total revenue from operations increased to Rs 12,192 crore in the second quarter of this fiscal, as compared to Rs 10,952 crore in the year-ago period, Sun Pharma said in a regulatory filing. Sun Pharma Managing Director Dilip Shanghvi noted that the US FDA's acceptance of deuruxolitinib NDA for the treatment of moderate to severe alopecia areata marked an important milestone for the company. READ MORE

Sun Pharma share price performance

During the October–December 2023 quarter, shares of the company rose 8.69 per cent. In comparison, the Nifty50 index during the period gained 10.65 per cent, as per Trendlyne data.